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Objective: ABI-007 is a novel Cremophor
w EL-free nanoparticle albumin-bound paclitaxel.
This Phase I study was designed to evaluate tolerability and determine recommended dose
for Japanese patients when ABI-007 was administered in every-3-week schedule.
Pharmacokinetics of paclitaxel was also assessed.
Methods: Patients with advanced solid tumors refractory to standard therapy received a
30 min intravenous infusion of ABI-007 every 3 weeks without pre-medications at 200, 260
or 300 mg/m
2, respectively. Tolerability and recommended dose were determined by the
standard ‘3 þ 3’ rule.
Results: No dose-limiting toxicity was observed, despite the dose escalation. In another
cohort, 260 mg/m
2 was re-evaluated and resulted in no dose-limiting toxicity. Grade 3 or 4
neutropenia was reported for the majority of patients (n ¼ 8) but no incidence of febrile
neutropenia. Non-hematological toxicities were generally mild except for Grade 3 sensory
neuropathy (n ¼ 3). Pharmacokinetic study demonstrated the area under the curve of pacli-
taxel increased with increasing the dosage, and comparable pharmacokinetic parameters to
the western population. Partial response was observed in three non-small cell lung cancer
patients. Two of whom had received docetaxel-containing chemotherapy prior to the study.
Conclusions: ABI-007 administered in every-3-week schedule was well tolerated up to
300 mg/m
2, and recommended dose was determined at 260 mg/m
2 in consideration of efﬁ-
cacy, toxicities and similarity of pharmacokinetic proﬁle in western studies. Additional studies
of single-agent ABI-007 as well as platinum-based combinations, particularly in patients with
non-small cell lung cancer, are warranted.
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INTRODUCTION
ABI-007 (Abraxane
w; Abraxis Bioscience, Los Angels, CA,
USA) is a novel Cremophor
w EL (polyoxyethylated castor
oil)-free albumin-bound nanoparticle formulation of
paclitaxel. This formulation allows for a higher paclitaxel
concentration in the suspension, serving to reduce the admin-
istration volume and time. No pre-medication to prevent the
Cremophor
w EL-induced hypersensitivity reaction is needed.
In addition, non-polyvinyl chloride infusion system and
in-line ﬁltration are not necessarily applied given no leaching
of plasticizers (1,2).
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conducted in the USA, the dose of ABI-007 was escalated
from 135 to 375 mg/m
2, and maximum tolerated dose
(MTD) and recommended dose (RD) were established at
300 mg/m
2. It was exceedingly higher than that of solvent-
based paclitaxel (Taxol
w; Bristol–Myers Squibb, Princeton,
NJ, USA), 175 mg/m
2 (1). Dose-limiting toxicities (DLTs)
were keratitis, blurred vision, sensory neuropathy, stomatitis
and neutropenia. Maximum concentration (Cmax)a n dt h e
area under the curve from time zero to inﬁnity (AUCinf)o f
paclitaxel increased linearly over the ABI-007 dose range of
135–300 mg/m
2 administered over 30 min. Volume of distri-
bution of ABI-007 is characterized by the larger distribution
than solvent-based paclitaxel, indicating extensive extra-
vascular distribution of the drug (3). Cmax and AUCinf values
for individual patients correlated well with toxicities.
In the Phase III pivotal study of 454 patients with meta-
static breast cancer, Q3W schedule of ABI-007 260 mg/m
2
produced the superior outcome to the same schedule of
solvent-based paclitaxel, 175 mg/m
2: signiﬁcantly higher
response rate and prolonged time to progression [33% vs.
19% (P , 0.001) and 23.0 vs. 16.9 weeks (P ¼ 0.006),
respectively] and signiﬁcantly lower incidence of Grade 4
neutropenia, despite a 49% higher paclitaxel dose [9% vs.
22% (P , 0.001)] (4). The dosage and schedule used in this
Phase III study lead to the approved labeling worldwide.
According to the clinical utility and study data reported
overseas, ABI-007 seems to be an effective treatment. This
Phase I study aimed to evaluate tolerability, DLT and RD in
Japanese patients with solid tumors when administered in
Q3W schedule. Efﬁcacy, toxicity and pharmacokinetics (PK)
were also evaluated as secondary objectives, followed by the
evaluation on ethnic difference in PK.
PATIENTS AND METHODS
PATIENT ELIGIBILITY
Patients aged 20–74 years with histologically or cytologi-
cally diagnosed malignant solid tumors refractory to standard
therapies or for which there was no effective treatment were
eligible. They had to have an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0–2, and a life
expectancy of  60 days. Eligibility criteria also included
adequate renal, liver and bone marrow function, deﬁned as
serum creatinine (Cr)  1.5 mg/dl, serum total bilirubin (TB)
 1.5 mg/dl, aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) ,100 IU/l, respectively, serum
albumin  3.0 g/dl, white blood cell count  12 000/mm
3,
absolute neutrophil count  2000/mm
3, platelets  100 000/
mm
3 and hemoglobin  9.0 g/dl. Patients with prior exposure
to taxanes were eligible for the study. Key exclusion criteria
included the following: (i) surgery within 4 weeks; (ii) che-
motherapy within 3 weeks; (iii) radiotherapy within 3 weeks;
(iv) history of radiation to more than 30% of hematopoietic
marrow; (v) pre-existing sensory neuropathy  Grade 2; (vi)
pleural effusion and ascites that required drainage; (vii) brain
metastasis showing symptoms or requiring treatment; (viii)
hepatitis B or C virus or human immunodeﬁciency virus
infection; (ix) chronic steroid treatment; (x) pregnancy, lacta-
tion, suspicion of being pregnant; (xi) serious pre-existing
medical conditions such as uncontrolled infections, pulmonary
ﬁbrosis, diabetes, severe heart disease and psychogenic
disorders.
This study was approved by the Institutional Review
Board at the National Cancer Center and conducted accord-
ing to Japanese Good Clinical Practice guidelines. All
patients provided written informed consent prior to study
entry.
STUDY DESIGN AND TREATMENT
This Phase I, open label, dose-ﬁnding study was conducted
at National Cancer Center and National Cancer Center East.
ABI-007 was supplied by TAIHO Pharmaceutical Co.,
Ltd, Tokyo Japan. Each vial contained 100 mg of paclitaxel
and 900 mg of frozen-dried Albumin Human (United
States Pharmacopeia). The prescribed dose of ABI-007 was
prepared in 5 mg (paclitaxel)/ml of physiological saline as a
suspension. The drug was administered via 30 min i.v.
without pre-medication and in-line ﬁltration.
Evaluated dose levels were 200, 260 or 300 mg/m
2,a s
shown in Table 1, repeated every 3 weeks. The rationale for
selected dose range was the following: the upper level,
300 mg/m
2—MTD determined in a US Phase I study; the
middle level, 260 mg/m
2—the approved dose in the US/EU,
and the lower level, 200 mg/m
2—one dose level below MTD
examined in the foregoing Phase I study. The dose range
also factored in PK: linear PK of ABI-007 over the dose
range 80–300mg/m
2 and the same level and activity of
CYP2C8 and CYP3A4 between Japanese and Caucasians
(5). Dose escalation was capped at 300 mg/m
2. In the event
that MTD exceeded the cap, further steps in investigation
would be discussed among study sponsor, principal investi-
gator and medical experts.
The dose escalation followed the standard ‘3 þ 3’ rule.
Three patients were evaluated at the ﬁrst dose level, and in
the absence of DLTs, three additional patients were entered
at the next dose level. If one of the three patients encoun-
tered a DLT, another cohort was to be added at the same
dose level. The MTD was deﬁned as the dose level at which
two out of three to six patients experienced DLT. The RD
Table 1. Dose levels
Level Dose (mg/m
2) No. of patients entered No. of courses
1 200 3 9
2 260 6 23
3 300 3 14
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and consequently, a total of six patients were to be treated at
RD to further evaluate the safety proﬁle.
DLTs were pre-deﬁned as any of the following
drug-related toxicities that had occurred during the ﬁrst
course: (i) Grade 4 thrombocytopenia; (ii) Grade 3 thrombo-
cytopenia requiring platelet transfusion; (iii) Grade 4 neutro-
penia over 4 days; (iv) Grade 3 or 4 febrile neutropenia; and
(v) Grade 3 or 4 non-hematologic toxicity. Dose was
reduced by one level when DLT occurred in the ﬁrst course,
and reduction was allowed when the toxicities corresponding
to DLT or Grade 2 neuropathy occurred in the second course
or later.
PATIENT EVALUATION
Pre-treatment evaluation included a complete history and
physical examination, a complete blood count with differen-
tial, serum chemistry proﬁle, urinalysis including pregnancy
test, chest X-ray and electrocardiogram. Serum chemistry
proﬁle included electrolytes, Cr, urea nitrogen, TB, AST,
ALT, lactic dehydrogenase, alkaline phosphatase, total
protein, albumin and C-reactive protein. Baseline imaging
studies and serum tumor marker levels were obtained at the
discretion of treating physician. Toxicity assessment, phys-
ical examination and all blood tests except serum tumor
markers were repeated on a weekly basis.
Toxicities were graded according to Common
Terminology Criteria for Adverse Events (CTCAE), version
3.0. Patients were considered evaluable for toxicity if they
received at least one dose of the study drug. Objective
response to therapy was assessed every 4–6 weeks according
to Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.0 (6).
BLOOD SAMPLING AND PK ANALYSIS
Whole blood samples of 7 ml each were collected in 6 ml of
heparinized tube and 1 ml of K3-EDTA tube to determine
the PK of ABI-007 at time points: 0, 0.25, 0.5 (end of infu-
s i o n ) ,0 . 7 5 ,1 ,1 . 5 ,2 ,4 ,1 0 ,2 4 ,4 8a n d7 2h .H e p a r i n i z e d
samples were immediately centrifuged at 1000 g for 15 min
in 48C and resultant plasma was stored in aliquot, whereas
K3-EDTA samples were softly mixed in normal temperature.
These samples were stored at less than or equal to 2208C
until analyzed. The sample was analyzed for paclitaxel using
liquid chromatography/tandem mass spectrometry in Alta
Analytical Laboratory (El Dorado Hills, CA, USA). The
limit of quantiﬁcation for paclitaxel in plasma and whole
blood was 1.00 and 5.00 ng/ml, respectively, and the range
of reliable response in these samples was 1.00–500 and
5.00–5000 ng/ml, respectively.
PK parameters were determined from each patient’s whole
blood/plasma paclitaxel concentration proﬁle. They were
evaluated by non-compartmental analysis using the
WinNonlin software package (Ver4.1, Pharsight Corp., CA,
USA). The Cmax of paclitaxel was obtained directly from
experimental data. The elimination constant (lz) was
obtained by log-linear regression analysis of the terminal
phase of the whole blood/plasma concentration vs. time
proﬁle. The elimination half-life (t1/2) was determined by
taking the ratio of natural log of 2 and lz. The AUCinf was
estimated by summing the areas from time zero to the last
measured concentration–time point (AUC0–t), calculated
using the linear-logarithmic trapezoidal method, and the
extrapolated area. The dose–area relationship (i.e. total
ABI-007 dose divided by AUCinf) was used to determine
total body clearance (CL). The volume of distribution (Vz)
was determined by taking the ratio between CL and lz.
Table 2. Patient characteristics
Characteristics No. of patients
Total no. of patients 12
Male/female 10/2
Age (years)
Median 61
Range 45–69
ECOG performance status
03
19
Tumor type
NSCLC 6
Parotid gland 1
Ovary 1
Bladder 1
Pharyngeal and esophageal 1
Colon 1
Thymoma 1
Prior treatment
Surgery 9
Radiotherapy 3
Chemotherapy 12
No. of prior chemotherapy
11
24
 37
Prior taxane therapy
Yes
Solvent-based paclitaxel 1
Docetaxel 5
Solvent-based paclitaxel and docetaxel 2
No 4
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung
cancer.
406 Phase I study of ABI-007Descriptive statistics were used for baseline characteristics,
safety assessment, and PK variables. Regression analysis of
individual Cmax, and AUCinf vs. dose was performed to gain
an appreciation of PK linearity. The SAS software package
(ver8.2, SAS Institute, Inc., NC, USA) was used for statisti-
cal analysis.
RESULTS
PATIENTS AND TREATMENT
Between August 2006 and June 2007, 12 patients were
enrolled and treated in this study at two participating centers
in Japan. Patient characteristics are summarized in Table 2.
Most patients were male (83%) with a median age of 61
(range, 45–69) years and all patients were ECOG PS 0–1.
The predominant type of tumor was non-small cell lung
cancer (NSCLC). Nine patients had surgery for primary
tumors, seven had received more than three prior chemother-
apy regimens and eight had received prior taxane-containing
chemotherapy.
The patients were treated at the following dose levels:
200 mg/m
2 (Level 1, n ¼ 3), 260 mg/m
2 (Level 2, n ¼ 6)
and 300 mg/m
2 (Level 3, n ¼ 3). All were evaluable for
safety and PK, and 11 for efﬁcacy (one had no adequate
measurable lesions for RECIST criteria).
DLT, TOLERABILITY AND RD
No DLTs were observed through the dose escalation to the
highest Level 3; therefore, the MTD was not reached metho-
dologically. To decide on the potential RD, study sponsor,
medical advisor and principal investigators jointly reviewed
the reference data in the foreign studies (1,4,7) and favored
260 mg/m
2 from tolerability and safety perspectives,
particularly the development of cumulative neurotoxicity.
Additional three patients were then accrued to 260 mg/m
2
cohort to repeat the assessment. None of DLTs being
experienced by the additional patients, 260 mg mg/m
2,w a s
established as RD.
SAFETY
A total of 46 courses of ABI-007 was administered, and
the median number of courses administered per patient
was 3 (range, 1–11). No acute hypersensitivity reactions
were observed during the infusion period. The most
common toxicities were neutropenia, leucopenia, lympho-
penia, alopecia and sensory neuropathy. The incidences of
hematologic toxicities by dose level are shown in Table 3.
Grade 3 or 4 neutropenia was often experienced in more
than half of patients throughout the study; however, no
febrile neutropenia was observed. The median time to
onset of Grade 3 or 4 neutropenia was 15.0 (range, 8–34)
days, and the median time to recovery to ,Grade 2 was
6.5 (range, 3–14) days. There were no episodes of
 Grade 2 or greater thrombocytopenia, and anemia was
mostly mild. Frequent non-hematological toxicities were
sensory neuropathy, alopecia, arthralgia/myalgia and rash
(Table 4). The sensory neuropathy was manifested by par-
esthesia in a symmetric, stocking/glove distribution, and
the median time to the ﬁrst indication or exacerbation
from the baseline was 7 days. The severity of non-
hematologic toxicities was generally mild except for three
cases of Grade 3 sensory neuropathy at Level 2 (n ¼ 1)
and Level 3 (n ¼ 2), which cumulatively exacerbated from
Grade 1 observed in the ﬁrst week of the ﬁrst course
(range, 3–6 days from the administration) to Grade 3
during the third or later course (range, 3–11 courses from
the administration). Among the three patients who experi-
enced Grade 3 sensory neuropathy, one patient had
received taxane-containing chemotherapy prior to the
study. A variety of ocular toxicities including superﬁcial
keratopathy reported in the initial Phase I study of USA
were not observed in this study. Treatment delay occurred
in one patient at each Levels 2 and 3 due to the neuro-
toxicity, dose reduction occurred in two patients at each
Levels 2 and 3 due to the neurotoxicity, and treatment
was discontinued in three patients at each Levels 2 and 3,
comprising ﬁve patients with treatment-related neurotoxi-
city and one patient with unrelated neutropenia.
Table 3. Hematologic toxicities (all courses)
Dose levels Level 1 (200 mg/m
2) Level 2 (260 mg/m
2) Level 3 (300 mg/m
2) All
No. of patients (no. of courses) n ¼ 3 (9) n ¼ 6 (23) n ¼ 3 (14) n ¼ 12 (46)
C T C A E g r a d e 1 – 2341 – 2341 – 2341 – 234
Leucopenia 2 0 0 3 2 0 3 0 0 8 2 0
Neutropenia 1 1 0 1 3 1 1 2 0 2 6 2
Anemia 1 0 0 2 0 0 1 0 0 4 0 0
Thrombocytopenia 0 0 0 1 0 0 1 0 0 2 0 0
CTCAE, Common Terminology Criteria for Adverse Events.
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Eleven of 12 patients were evaluable for anti-tumor response
(Table 5). Partial responses were observed in three NSCLC
patients. Of them, two of whom had received docetaxel-
containing chemotherapy prior to the study. The ﬁrst
patient, entered at Level 1, had received 6 courses of
ABI-007, and the second and third patients, entered at
Level 2, 11 and 6 courses, respectively. The both respon-
ders in Level 2 attained disease control until the treatment
discontinuation due to the sensory neuropathy.
PHARMACOKINETICS
Blood samples for PK analysis were available from all of 12
patients following the ﬁrst course of treatment. A semi-log
plot of the mean values of paclitaxel concentration for each
dose level vs. time is shown in Fig. 1. After 30 min infusion
of ABI-007, the concentration of paclitaxel began to
decrease immediately upon cessation of the infusion with t1/2
of 17.3–27.3 h in the whole blood, which is nearly compar-
able with that of standard dose of solvent-based paclitaxel
(6), and the decline of paclitaxel concentration from
maximum was multiphasic.
The mean PK parameters of paclitaxel are summarized in
Table 6. Cmax,A U C 0–t and AUCinf of paclitaxel when admi-
nistered as a 30 min infusion of ABI-007 increased with
increasing dosage. CL and Vz of the blood sample showed
the small inter-patient variability, and the mean+SD values
(CV%) for CL and Vz at the dose level of 260 mg/m
2 were
18.1+2.33 (12.9 CV%) (l/h/m
2)a n d5 1 0 +96.8 (19.0
CV%) (l/m
2), respectively. These values slightly decreased
with increased dosage. It was considered that there was no
remarkable difference in calculated values of PK parameters
between whole blood and plasma. Regression analysis
suggested the dose-proportionality of ABI-007 within the
dose range in this study (R
2 of Cmax ¼ 0.4470, R
2 of
Table 5. Anti-tumor response
Tumor type Prior taxane
therapy
Response
Level 1 (200 mg/m
2) NSCLC þ PD
NSCLC þ PR
Parotid gland þ PD
Level 2 (260 mg/m
2) NSCLC þ PD
NSCLC 2 PR
Ovary þ PD
NSCLC þ PR
Colon 2 PD
Thymoma 2 SD
Level 3 (300 mg/m
2) Bladder 2 SD
NSCLC þ NE
Pharyngeal and
esophageal
þ SD
PD, progressive disease; PR, partial response; SD, stable disease; NE, not
evaluable.
Table 4. Non-hematologic toxicities (all courses)
Dose levels Level 1 (200 mg/m
2) Level 2 (260 mg/m
2) Level 3 (300 mg/m
2) All
No. of patients (no. of courses) n ¼ 3 (9) n ¼ 6 (23) n ¼ 3 (14) n ¼ 12 (46)
CTCAEgrade 1–2 3 1–2 3 1–2 3 1–2 3
Sensory neuropathy 1 0 5 1 1 2 7 3
Alopecia 3 0 4 0 3 0 10 0
Myalgia 0 0 6 0 3 0 9 0
Rash 2 0 4 0 1 0 7 0
Arthralgia 1 0 4 0 2 0 7 0
Asthenia 2 0 2 0 2 0 6 0
Motor neuropathy 0 0 3 0 2 0 5 0
Nausea 2 0 1 0 1 0 4 0
Anorexia 3 0 1 0 0 0 4 0
Vomiting 1 0 2 0 0 0 3 0
Diarrhea 2 0 0 0 0 0 2 0
Stomatitis 0 0 0 0 2 0 2 0
Grade 4 toxicities were not observed.
408 Phase I study of ABI-007AUCinf ¼ 0.7177); however, it was difﬁcult to establish the
linearity due to those narrow dose range and small data size.
DISCUSSION
In the Phase I study where ABI-007 was administered in
Q3W schedule in Japanese patients, no DLT occurred at any
dose level of 200, 260 and 300 mg/m
2. Because MTD was
not reached by the 3 þ 3 rule, selection of RD was attributed
to the consideration of reasonable tolerability, toxicities and
PK proﬁle. Since paclitaxel treatment was characterized for
the cumulative neurotoxicity, dose selection also took into
account the development of sensory neuropathy throughout
the study. Consequently, 260 mg/m
2 was reassessed as
potential RD and established as RD in the absence of appli-
cable DLT. Outcome of sensory neuropathy in all treatment
courses also provided the justiﬁcation for the feasibility of
260 mg/m
2 (Table 7). Among 260 and 300 mg/m
2 cohorts,
every patient experienced neuropathic events, in
which Grade 3 or 4 event was more frequent in 300 mg/m
2
(two out of three patients) than in 260 mg/m
2 cohorts (one
out of six patients). Moreover, all the three patients in
300 mg/m
2 cohort discontinued the treatment due to
neuropathic events as opposed to two out of six patients in
260 mg/m
2 cohort.
In terms of treatment-related toxicities, Grade 3 or 4 neu-
tropenia was experienced in 15 of 46 treatment courses
(32%). Nonetheless, no febrile neutropenia was observed.
Median duration of recovery from Grade 3 or 4 to ,Grade
2 was 6.5 days (range, 3–14). No treatment delay was
caused by neutropenia. In addition, platelet decrease
 Grade 2 was not observed throughout the study. On the
whole, hematological toxicities were mild. In regard to
sensory neuropathy, the median time to the ﬁrst indication
or exacerbation from the baseline was 7 days, which
Figure 1. (a) Mean whole blood concentration–time proﬁles of paclitaxel. (b) Mean plasma concentration–time proﬁles of paclitaxel.
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Especially for Grade 3 sensory neuropathy, the indication or
exacerbation fell within the ﬁrst week of the ﬁrst course,
ranging from 3 to 6 days; the time to improve from Grade 3
to Grade 2 or 1 was 21, 26 and 46 days in the respective
cases. Although the improvement tended to delay when
compared with median 22 days in a previous Phase III
study (4), it still remains controversial because of the great
difference in the sample sizes between the two studies.
Meanwhile, other non-hematological toxicities including
mucositis—the DLT of the US Phase I study—were gener-
ally mild to moderate up to 300 mg/m
2.
PK proﬁles of ABI-007 have revealed the small inter-
patient variability, and the AUC and Cmax of paclitaxel
increased with increasing the dosage. In whole blood
samples, there was a signiﬁcant correlation between the
doses and PK parameters. The linearity was uncertain in the
face of wide conﬁdence interval (CI) with small sample size,
however, presumable from the other reported data showing
the linearity over a wide dose range: 80–300 mg/m
2 (2)a n d
PK equality between Japanese and western population (3).
Anti-tumor response was demonstrated in the patients with
NSCLC including the patients who had received prior
taxane-containing therapy.
Multiple previous studies of ABI-007 also reported the
promising data in the patients with NSCLC. In a Phase II
trial, 260 mg/m
2 of ABI-007 was administered alone in the
same Q3W schedule as our study in the ﬁrst-line setting,
overall response rate was 16.3% (95% CI, 5.24–27.31%)
and the disease control rate was 48.8% (95% CI, 33.90–
63.78%) (8). More recently, weekly (QW) schedule of
ABI-007 was also reported: 125 mg/m
2 of ABI-007 was
administered in monotherapy on days 1, 8 and 15 every 4
weeks, the response rate was 30% ((95% CI, 16–44%) and
the disease control rate was 50% (95% CI, 35–66%) (9).
Despite the higher incidence of  Grade 3 neutropenia and
sensory neuropathy relative to the Q3W schedule, QW sche-
dule was well tolerated and active.
In conclusion, no DLT observed at any dose levels, and
ABI-007 was well tolerated up to 300 mg/m
2 in Japanese
Table 6. PK parameters of paclitaxel
200 mg/m
2
(n ¼ 3)
260 mg/m
2
(n ¼ 6)
300 mg/m
2
(n ¼ 3)
Mean CV
(%)
Mean CV
(%)
Mean CV
(%)
Whole blood
Cmax (ng/ml) 9430 28.3 11 635 13.0 13 833 15.3
AUCinf (ng h/ml) 10 360 22.0 14 593 13.7 19 138 12.2
t1/2 (h) 24.3 10.9 19.5 7.9 18.3 1.9
CL (l/h/m
2) 19.9 21.6 18.1 12.9 15.8 11.2
Vz (l/m
2) 689 15.3 510 19.0 417 9.7
Plasma
Cmax (ng/ml) 9040 34.0 12 000 17.6 12 700 20.5
AUCinf (ng h/ml) 9146 29.6 13 330 20.7 16 271 11.2
t1/2 (h) 29.0 17.7 20.8 19.5 19.8 9.8
CL (l/h/m
2) 23.1 26.4 20.2 21.5 18.6 10.6
Vz (l/m
2) 935 11.7 620 36.9 527 7.0
PK, pharmacokinetic; CV, coefﬁcient of variation; Cmax, maximum
concentration; AUCinf, area under the concentration–time curve up to 1
hours; t1/2, terminal elimination half-life; CL, clearance; Vz, volume of
distribution based on terminal phase.
Table 7. Grade change in sensory neuropathy (all courses)
Level Case Before administration Course no.
1 234567891 0 1 1
L e v e l 1 1 - 20 00111 1
a —————
L e v e l 22 - 1 1 2——————————
2 - 20 1111111122 3
a
2 - 3 0 0 1—————————
L e v e l 3 3 - 10 11222 3
a —————
3 - 20 1112 2
a ——————
3-3 0 2 2 3
a ————————
L e v e l 2 2 - 40 11122 2
a —————
2 - 5 0 1——————————
2 - 6 0 1 1—————————
—, end of study.
aStudy-off due to sensory neuropathy.
410 Phase I study of ABI-007patients. RD in this schedule was determined to be 260 mg/
m
2 in consideration of efﬁcacy, toxicities and similarity of
PK proﬁle in the western studies. Additional studies of
single-agent ABI-007 and platinum-based combinations are
warranted.
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